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Abstract  
AIM: The purpose of the study was to determine the levels of Copper (Cu), selenium (Se), Zinc 
(Zn), Lead (Pb) and Lithium (Li) in patients in Accra and Pantang Psychiatric Hospitals in Ghana 
since no data exist.  
SUBJECTS AND METHODS: Simple random sampling of age-matched subjects was used to 
recruit 81 schizophrenics and 25 mentally healthy controls in 2012. Serum levels of Cu, Se, Zn, Pb 
and Li were determined by flame atomic absorption spectroscopy (FAAS).   
RESULTS: Mean levels were as follows: Cut 766 ± 250 µg/L and Cuc 855 ± 270 µg/L (p = 0.168). 
Set 149 ± 72 µg/L and Sec 108 ± 61 µg/L (p=0.009). Znt 702 ± 438 µg/L and Znc 1007 ± 593 µg/L (p 
= 0.028). Pbt 1.38 ± 0.05 µg/L and Pbc 0.10 ± 0.05 µg/L (p = 0.000). Li levels for the test group (Lit) 
was 4077 ± 2567 µg/L, whiles that of the controls was undetectable < 0.02 µg/L. Se, Pb and Li 
levels were significantly higher in schizophrenic patients compared to controls. While Zn and Cu 
levels were lower in the same group.  
CONCLUSION: Trace elements dysmetabolism exist among Ghanaian schizophrenics and 
monitoring is essential to avoid the adverse effects of metal overload or deficiency. 
  
 
 
 
 
 
Introduction 
In 2001, 450 million people worldwide 
suffered from some form of mental disorder or brain 
condition [1]. Of the 21.6 million people living in 
Ghana, 650,000 were reported suffering from severe 
mental disorders and a further 2,166,000 from 
moderate to mild mental disorders in 2007 (WHO, 
2007) [2]. Globally, the most frequent disorders are 
schizophrenia, anxiety disorders, depression, 
somatoform and substance abuse disorders [3].
 
Traditional prevalence or “core,” is studies-
generated estimates based on the population residing 
within a defined catchment [4]. The prevalence 
estimates would therefore differ within lifetime, period, 
and point prevalence [4, 5]. Furthermore, in 
developing countries the proportion of cases with 
acute onset schizophrenia was twice as high as in 
developed countries [5]. This could be an 
underestimation [6].  
Schizophrenia is characterized by symptoms 
that may include delusions, hallucinations, catatonia, 
negative symptoms, and disorganized speech or 
behavior. Genetic pre-disposition, pregnancy and its 
complications are said to be some of the risk factors, 
while viral infections and subsequent autoimmune 
reactions are causative factors [7].  
Trace elements (TE) are suspected to be 
causative agents in the development of schizophrenia 
although the mechanism is poorly understood [8]. Cu, 
a component of several enzymes linked to dopamine 
synthesis, may play a role in schizophrenia by 
exacerbating or perpetuating dopaminergic 
dysregulation. Furthermore, it is suggested that 
ceruloplasmin elevation in schizophrenia is specific, 
and not simply an elevation of plasma copper-
containing oxidative enzymes [9]. Abnormalities in Cu 
metabolism have been demonstrated in 
schizophrenics [10, 11]. This link is attributed to 
several metalloenzymes associated with dopamine 
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synthesis and regulation [12]. Dopamine and other 
catecholamines act as important hormones and 
neurotransmitters of the central and peripheral 
nervous system and have functions in the brain that 
control emotions [13, 14] and cognition [15].
 
Se is an integral component of glutathion 
peroxidase (GPx) which protects against reactive 
oxygen species (ROS). Selenoprotein R and 
thioredoxin, another selenoprotein, play similar 
protective roles [16]. Because oxidative stress 
increases DNA damage, Se deficiency could result in 
a higher mutation rate, increasing the likelihood that 
the sequence of a schizophrenia-related genetic 
region will be altered [17-18].   
Zinc deficiency in the latter part of gestation 
impair fetal growth, brain size, total brain cell count, 
and the period of macroneuronal proliferation [19-20] 
and neurotransmitter functions. One explanation is 
attributed to the failure of thymidine incorporation into 
brain DNA, a decreased rate of protein synthesis and 
a smaller hippocampus [21]. Low and normal serum 
zinc levels have been demonstrated in studies with 
Bangladeshi and Turkish schizophrenics, respectively 
[11, 22].  
Lead (Pb
2+
) is a neurotoxicant present in the 
environment and capable of producing biochemical, 
anatomical, and neurological changes that altogether 
produce behavioural changes in human development 
and the manifestation of schizophrenia later in life. Pb 
exposure in the course of development manifests in 
expressions of increased spontaneous activity, 
decreased social interaction, and learning deficits 
presents also in schizophrenics [23].
 
Lead is a potent antagonist of the N-methyl-d-
aspartate (NMDA) receptor (NMDAR). It is the 
reduced expression of NMDAR that is ideated to be 
associated with the pathophysiology of the disease 
[24]. Furthermore, reduced dentate gyrus (DG) 
neurogenesis has been demonstrated in an animal 
model using phencyclidine which is an NMDAR 
antagonist [25].   
The biochemical mechanisms of action of Li 
appear to be extraordinarily complex, multifactorial 
and strongly intercorrelated with the functions of other 
elements, drugs, enzymes, hormones, vitamins, 
growth and transforming factors [26]. Rats on a Li-
deficient diet demonstrated suppressed liver-press 
avoidance behavior [27]. Furthermore, rats on a Li-
deficient diet exhibited diminished wheel-running 
activity, decreased response to handling and lower 
aggression in social interactions [28]. Evidence linking 
low Li intake with altered behavior and 
aggressiveness in humans has been reported [29].
 
Genetic factors have also been implicated in the 
metabolism of Li. The precise therapeutic mechanism 
of Li remains unknown, but may involve the circadian 
clock. Molecular components of the circadian clock 
are known to be Li sensitive [30-34]. Li also inhibits 
glycogen synthase kinase 3β (GSK3β) [33], which in 
turn regulates protein turnover and stability in the 
clock network by phosphorylating target proteins, 
thereby modulating circadian rhythms [34].  
The aim of the study therefore was to 
determine deficiency, toxicity or dysmetabolism of Cu, 
Se, Zn, Pb and Li in Ghanaian schizophrenic patients 
in Accra since no such data exist. 
 
Subjects and Method 
This was a case-control study. Ethics 
approval was obtained from the Ghana Health Service 
(GHS-ERC: 16/05/12) and the University of Ghana 
School of Allied Health Sciences (SAHS-
ET./10285645/AA/26A/2012-2013). A total of 81 
clinically diagnosed psychiatric patients made up of 42 
males and 39 females, from the Pantang Hospital 
(Accra) and 25 apparently mentally healthy age-
matched and sex-matched controls (13 males and 12 
females) were recruited for the study in July 2013. 
Simple random sampling was used to recruit subjects. 
Psychiatric patients should have been on admission 
for not less than five (5) years. 
 
Treatment of Glassware 
All glassware and tubes were soaked in 10% 
(w/v) HNO3 (Fluka, Germany) overnight and then 
rinsed with deionized water. 
 
Digestion Protocol for Sample  
Digestion of samples was done according to 
standard trace element analysis protocols using 
milestone microwave labstation ETHOS 900 (INSTR: 
MLS-1200 MEGA) programme (Table 1).  
Table 1: Microwave digestion programme. 
Step Time Power Pressure 
Temp 
o
C 
[1] 
Temp 
o
C 
[2] 
1 00:02:00 250 100 400 500 
2 00:02:00 0 100 400 500 
3 00:06:00 250 100 400 500 
4 00:05:00 400 100 400 500 
5 00:05:00 650 100 400 500 
Vent:00:05:00                                  Rotorctrl on                     Twist on 
(Milestone Acid Digestion Cookbook update, 1996) 
 
After cooling, the digestate was then 
transferred into a volumetric flask and diluted to 20 mL 
with deionized water. The diluted digestate was 
assayed for the level of Cu, Se, Zn, Pb and Li using 
VARIAN AA 240FS-Atomic Absorption Spectrometer 
(Kungsbacka, Sweden) along with standards of high 
purity metals from Teknolab AS (Kungsbacka, 
Sweden) and reference material Seronom
TM
 Trace 
Elements Serum L-1, L-2 (Billingstad, Norway) under 
conditions in Table 2. Blank samples were also 
digested and analyzed along with the samples. 
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Table 2: Analytical conditions of elements. 
Element Wavelength 
nm 
Lamp 
Current 
mA 
Slit 
Width 
nm 
Fuel Support 
Se 196.0 10 1.0 ACETYLENE   AIR 
Pb 217.0 5 1.0 ACETYLENE   AIR 
Cu 324.7 4 0.5 ACETYLENE   AIR 
Li 670.8 5 1.0 ACETYLENE   AIR 
(VARIAN, 1989) 
 
Quality Assurance and Control Measures 
The method detection limit was calculated as 
the mean of the blank concentration and three times 
the standard deviation. Values below detection limit of 
the instrument were replaced by the method detection 
limit divided by the square root of two. Control 
samples and standards were measured. Linearity was 
assessed by the calibration curve of all the elements 
measured. Replicate measurement for each sample 
was taken to ensure precision. 
 
Statistical Analysis 
The statistical analyses of the data was done 
using SPSS (Statistical Package for Social Sciences) 
version 16.0. Means ± standard deviation were 
determined for quantitative variables. Chi-square was 
used for categorical data and independent t-test for 
demographic data. Comparison of Cu, Se and Zn   
levels between the psychiatric patients and the control 
group were performed with unpaired t-test. 
Abnormally distributed data (Pb) was analyzed with 
Wilcoxon-Mann/Whitney test. Pearson’s correlation 
was used to test the relationship between the trace 
elements, gender and age. P-values ≤ 0.05 were 
considered statistically significant.  
 
Results 
Demographic Data 
A total of 81 clinically diagnosed psychiatric 
patients (20-57 years), made up of 42 males (51.2%) 
and 39 females (48.1), and 25 apparently mentally 
healthy controls (13 males and 12 females) (23-51 
yrs) were recruited for the study. The mean age was 
32.32 ± 0.84 yrs for cases and 33.64 ± 1.64 years for 
controls. Cases were found to be on haloperidol (0.5 
mg – 3 mg). 
 
Trace Elements Concentrations 
The mean Cu, Se, Zn and Pb levels for the 
test and control groups were 766 ± 250 g/L, 149 ± 72 
g/L, 702 ± 438 g/L, 1.38 ± 0.05 g/L and 855 ± 270 
g/L, 108 ± 61 g/L, 1007 ± 593 and 0.10 ± 0.05 g/L, 
respectively. Graphical representations of Cu, Se, Zn, 
Pb and Li concentrations of the subjects are shown in 
Figure 1, 2, 3, 4 and 5, respectively. Statistical 
differences found between the psychiatric patients 
and the controls for the elements Cu, Se, Zn and Pb 
were p = 0.168, p = 0.009, p = 0.028 and p = 0.001, 
respectively (Table 3).  
 
Table 3: The levels of trace elements of Schizophrenic patients 
(cases) and controls. 
 
Controls 
 
 Cases p values 
 
N Mean 
 
N Mean  
Copper (µg/L)
a 
25 855 ± 270 
 
81 766 ± 250 0.168 
Selenium (µg/L)
b 
25 108 ± 61 
 
81 149 ± 72 0.009 
Zinc (g/L)
c
 25 1007 ± 593 
 
81 702 ± 438 0.028 
Lead (µg/L)
d 
25 0.10 ± 0.05 
 
81 1.38 ± 0.05 0.001 
Lithium (g/L) 25 BDL 
 
81 4077 ± 2567 - 
a, b,c 
Independent t-test; 
d 
Wilcoxon - Mann/Whitney Test; BDL = Below Detection Limit 
 
Li levels could be detected in only 16 samples 
of the test group, giving a mean value of 4077 ± 2567 
g/L. The controls were also below the detection limit 
of the equipment (< 0.02 g/L). Therefore, only 
descriptive statistics was done for Li (Table 3). Values 
that could not be detected by the FAAS were replaced 
with the method detection limit (MDL) which is:  
MDL= Mean of Blank Concentration *3*SD, 
Non Detected Values=MDL/√2 
 
Table 4: The levels of trace elements in Psychiatric patients 
and controls according to gender. 
  Cu 
(g/L) 
Se 
(g/L) 
Zn 
(g/L) 
Pb 
(g/L) 
 Li 
(g/L) 
Cases  Males 775±270 124±52* 639±439 0.48±0.28  3233±1038 
 Females 757±230 181±82* 774±433 1.63±0.75  3549±1341 
Controls Males 799±320 113±77 945±539 0.12±0.05  BDL 
 Females 916±200 102±39 1064±609 0.08±0.04  BDL 
* = 0.05; BDL = Below Detection Limit. 
 
Female values were higher in all trace 
elements except for Cu. However, for the control 
group, copper was higher in males (Table 4). 
Furthermore, females had very high Se (181 ± 82 
g/L) compared to males (124 ± 52 g/L) (p=0.05) 
and low Zn (639 ± 439 g/L) compared to females 
(774 ± 433 g/L) (p>0.05) (Table 4). 
 
Figure 1: Different levels of copper (Cu) in the subjects. The test 
group showed significantly higher Cu levels than the controls. 
 
There was no correlation between the levels 
of trace elements and the age or gender of the 
participants. A positive correlation existed between Li 
and Pb (p=0.023) (Table 4). 
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Figure 2: Selenium (Se) levels in all the subjects. Significantly 
higher levels were observed in the test group compared to the 
controls. 
 
Discussion 
Mean Cu level of the Case group was 766 
g/L and the control group was 855 g/L. Values 
obtained for the Case group were statistically 
insignificant compared to the control group. Similarly, 
in the study of Nechifor et al. [35] no significant Cu 
differences were observed between cases and 
controls. On the contrary, the mean value of Cu for 
schizophrenic cases was 720 g/L while that of the 
Control group was 590 g/L in another study. 
Differences were statistically significant [9].
 
Yanik et 
al. [11] also reported of similar values; 980 g/L 
(Cases) and 760 g/L (control group) (p<0.05). 
However, higher values of 1174 g/L for 
Schizophrenic cases and 1056 g/L for controls with 
differences that were statistically significant have been 
reported. Altered levels of trace elements in 
schizophrenic patients may be a consequence of 
antipsychotic treatment [10]. 
 
Figure 3: The levels of zinc (Zn) in the test group and the controls. 
Zn levels were significantly higher in the test group than the control. 
A high level was observed for case 69 which was complemented by 
very low selenium levels (Figure 2). 
 
Normal brain functioning depends on the role 
of the Cu-containing enzyme dopamine -b-
hydroxylase converting dopamine into norepinephrine. 
Other enzymes such as lysyl oxidase (responsible for 
collagen synthesis) or monoamine oxidase A and B 
(the enzyme that eliminates dopamine) all contain 
copper. Therefore diminished copper impair these 
functions. On the contrary excess Cu will also reduce 
Zn-thionein and CuZnSOD, and other enzymes 
required for serotonin secretion as a result of 
competitive absorption with Zn, resulting in diminished 
Zn absorption. These aforementioned antioxidants are 
relevant in the maintenance of Cu-Zn homeostasis 
and failure to regulate excess Cu will lead to oxidative 
stress and damage. Dysmetabolism of these metals 
as well as disturbances of the dopamine/ 
norepinephrin pathway have been implicated in 
schizophrenia [36].  
 
Figure 4: The levels of lead (Pb) in the test group and the controls. 
Pb levels were significantly higher in the test group than the control. 
Case 49 had very high Pb levels accompanied by very low 
selenium levels (Figure 2). 
 
Se was 149 g/L (cases) and 108 g/L 
(control). Thus, Se was higher in the Schizophrenic 
group above the reference interval and statistically 
significant when compared to the control group (p= 
0.001). The mean value obtained for the control group 
was similar to that obtained in a previous study (123 
g/L) [37]. Significantly similar higher Se levels in 
schizophrenics were reported by Kharb et al. [38].  In 
that study Se levels of cases and controls were 134 
g/L and 101 g/L, respectively.  
 
Figure 5: The levels of lithium (Li) in the test group and the controls. 
Most of the control levels were below the detection limit. However, 
case 60 showed very high Li levels accompanied by very low 
selenium levels (Figure 2). 
 
Differences were attributed to geographical 
locations and soil Se levels. Yanik et al. [11] also 
Asare et al. Trace Elements in Ghanaian Clinically Stable Schizophrenics 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2014 Jun 15; 2(2):293-298.                                                                                                                                                                         297 
 
reported of a higher Se level in Schizophrenics (71.65 
g/L) compared to Controls (69.65 g/L). Differences 
however, were insignificant. Low blood Se 
concentrations in schizophrenic patients on clozapine 
have been reported; 101g/L (cases) verses 116 g/L 
(control), with differences being significant [39]. That 
study however, could not attribute the low Se to 
clozapine.  
Some authors have pointed out that the 
geography of schizophrenia may have possible links 
with Se and calcium deficiencies [40, 41]. However, it 
is unknown whether schizophrenics display selenium 
deficiency prior to diagnosis. Tada et al. [42] for 
example, discovered elevated selenium in the hair of 
male but not female patients. In contrast, Alertsen et 
al. [43] found no difference between the levels of 
selenium in the serum and blood of Norwegian 
schizophrenics and controls. 
In this study, the mean Zn level was 1007 
g/L for the control group compared to 702 g/L for 
the case group.  Similar low Zn level was obtained in 
the schizophrenic group (600g/L) in another study 
[35] compared to 890 g/L for the control group. In 
that study differences were significant and treatment 
raised the Zn levels appreciably. Zn plays a very 
complex role in the brain and Zn deficiency is 
postulated in the pathogenesis of schizophrenia [44]. 
Pfeiffer and Ilier [45] showed a lower plasma Zn level 
coupled with excess Cu in schizophrenic patients and 
Zn loss in the hippocampus of schizophrenic patients 
has also been demonstrated [46]. On the contrary, 
another study did not observe any significant 
difference between Zn levels of cases and controls 
[11]. In a similar study, serum Zn was lower among 
schizophrenic criminals compared to schizophrenic 
non-criminals (680 g/L and 810 g/L, respectively) 
with significant differences [47].
 
 Thus, low serum Zn 
in major depression is a sensitive marker of treatment 
resistance and of the immune/inflammatory response 
in mental illness [48].  Furthermore, Zn deficiency 
exacerbates loss in blood-brain barrier integrity 
induced by hyperoxia [49].
 
Pb levels in the case group and control group 
were 1.38 g/L and 0.10 g/L, respectively. 
Statistically, differences were significant (p = 0.001).  
Furthermore, case 49 (Figure 4), demonstrated very 
high Pb levels (12 g/L), with corresponding low Cu 
and Se values (Figure 1 and 2, respectively). Prenatal 
Pb exposure and schizophrenia has been argued [50, 
51]. The possible neurobiological connection with Pb 
exposure could be due to the fact that N-methyl-d-
aspartate receptor (NMDAR) may be affected by the 
antagonistic effect of Pb on NMDA thereby reducing 
the function of NMDAR which is involved in the 
pathophysiology of the disease [52]. Generally, 
exposure to such insults from the environment and 
damage or alteration to the developing central 
nervous system may be associated with 
schizophrenia and other mental disorders [53-55].   
Li levels in this study were below the 
detectable limit in all control subjects and majority of 
the cases. However, very high Li observed in case 60 
(Figure 5) corresponded to a very low Se level (Figure 
2). Much as Li may act as mood stabilizer, information 
on its efficacy is inconsistent [56]. Adjunctive Li and 
anticonvulsants for the treatment of schizophrenia 
seem to lack the necessary evidence [57]. The dearth 
of Li levels of schizophrenic patients is also 
problematic.  
In conclusion, Se, Pb and Li levels were 
significantly higher in schizophrenic patients 
compared to controls. Zn and Cu levels were 
significantly lower in the cases than the controls. 
Female Se levels were extremely high approaching 
toxic levels while male Zn levels were extremely low 
approaching deficiency levels. TE dysmetabolism 
exist among schizophrenics and monitoring of TE is 
essential to avoid the adverse effects of metal 
deficiency and/or overload in tandem with mental 
disease. To the best of our knowledge this data is the 
first on schizophrenics and trace elements in Ghana. 
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